Coagulants - Adverse effects
Research News and Information

Sunday, November 22, 2009

The use of recombinant activated factor VIIa in coagulopathic traumatic brain injuries requiring emergent craniotomy: is it beneficial?

29 Sep 2009 OBJECT: The role of recombinant activated factor VII (rFVIIa) in traumatic brain injury (TBI) has not been well established. This study evaluates the outcomes of using rFVIIa as first-line therapy in patients with a severe TBI requiring emergent ... Read more...

rFV11a and paediatric open-heart surgery: thrombosis in the cardiopulmonary bypass circuit in spite of adequate markers of anticoagulation.

30 May 2009 Recombinant activated factor V11 (rFV11a) is a relatively new procoagulant agent and its place in surgical practice continues to be investigated. We report the use of rFV11a to help manage bleeding in the operating theatre in a neonate, following ... Read more...

Quantifying the source of infection for HIV-infected hemophiliacs in the U.K. from 1979 to 1984.

29 Apr 2009 There is considerable literature on the risk of HIV infection for individuals suffering from hemophilia A in the United Kingdom (U.K.) during the period 1979-1984 when the sources of Factor VIII clotting factor were contaminated with HIV. Toward the ... Read more...

Latest indexed articles for 'Coagulants - Adverse effects'

These are the very latest articles for this heading:

• The use of recombinant activated factor VIIa in coagulopathic traumatic brain injuries requiring emergent craniotomy: is it beneficial? 29 Sep 2009
• Prothrombin complex concentrate and fatal thrombosis: poor evidence to implicate a relatively safe drug. 30 Aug 2009
• rFV11a and paediatric open-heart surgery: thrombosis in the cardiopulmonary bypass circuit in spite of adequate markers of anticoagulation. 30 May 2009
• Quantifying the source of infection for HIV-infected hemophiliacs in the U.K. from 1979 to 1984. 29 Apr 2009
• Evidence-based Emergency Medicine/Critically Appraised Topic. The efficacy of recombinant activated factor VII in severe trauma. 12 Mar 2009
• The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease. 27 Feb 2009
• Haemophilia patient had variant CJD agent in spleen. 16 Feb 2009
• Efficacy of homeopathically potentized antimony on blood coagulation. A randomized placebo controlled crossover trial. 8 Feb 2009
• Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate. 30 Jan 2009
• Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience. 30 Oct 2008
• Recombinant activated factor VII use in the emergency department. 29 Sep 2008
• Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage. 30 Aug 2008
• An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A. 29 Jun 2008
• Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation. 23 Jun 2008
• Formulary management of recombinant factor VIIa at an academic medical center. 11 May 2008
• Fatal thrombotic event after infusion of recombinant activated factor VII after cardiac surgery. 10 May 2008
• Recombinant clotting factors. 29 Apr 2008
• Current use of biologicals in thrombosis and haemostasis. 29 Apr 2008
• Applicability and safety of recombinant activated factor VII to control non-haemophilic haemorrhage: investigational experience in 265 children. 22 Apr 2008
• Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. 2 Apr 2008

See a longer list of these articles.

Technical information about 'Coagulants'

Definition: Exogenous substances used to promote blood coagulation. The endogenous BLOOD COAGULATION FACTORS are considered to be coagulants only when administered as drugs.

Registry Number: 0

Descriptor UI: D003029

Alternative terms: Coagulants;

Related Mesh Headings: Blood Coagulation Factors; Thrombin;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.502.270;

Online Note: search HEMOSTATICS 1966-74

History Note: 75; was see under HEMOSTATICS 1963-74

Technical Notes: consider also BLOOD COAGULATION /drug eff